How does PARI create value in new aerosol therapy development projects for pharmaceutical partners, caregivers, physicians? PARI focuses on a comprehensive approach that incorporates the following aspects:

Superior performance over other device platforms:

■ Increased compliance due to fast treatments, portability
■ Goal=treatments < 3 minutes
■ High drug payload
■ Less drug needed in low volume formulations
■ Potential to lower adverse events
■ Targeted or systemic therapies
■ Tight geometric standard deviation (GSD) of droplet
   distribution
■ As needed, device can be optimized for the formulation
   and the disease
■ High patient satisfaction

■ Key aspects of drug and device project can be
   performed at PARI with experienced teams.
■ Multi-disciplinary project teams consisting of experts
   in engineering and pharmaceutical sciences

■ PARI knows strengths of the device better than
   anyone.  Knowledge leads to optimized drug +
   device
■ Years of experience with formulations for eFlow and
   novel formulation approaches
■ Current drugs can be re-invented or new aerosol
   therapies can increase value and competitive edge

■ PARI is the Gold Standard in Clinical Trials for
   Nebulized Medications
■ 80+ studies/posters on development topics
■ On-time delivery of devices for Clinical Trials

■ Supply Agreements ensure supply of devices and
   involve partner in modifications

■ High reproducibility of the device

■ PARI licenses the above technology for specific drugs
  and indications. Same drug for same indication is
  protected under license.